RxDoctor Payments Data

Melissa Vyfhuis, MD

Radiation Oncology · Baltimore, MDNPI 1801214689

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,675 of the $2,143 with a category attached, or 78.1%. It is spread thinly across 34 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $635 and has fallen 53.1% since, to $298 in 2025.

$2,143in general payments, 2019–2025

Across 66 payments — averaging $32.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Elekta, Inc.$399
  • Merck$166
  • Daiichi Sankyo Inc.$136
  • Siemens Medical Solutions USA, Inc.$134
  • Myovant Sciences Inc.$96
  • Medtronic$96
  • plus $1K from 28 others

What the payments were for

  • Travel & lodging$39919%
  • Food & beverage$1,67578%
  • Education$703%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,143 in reported general payments places this provider in the 70th percentile of 108 radiation oncology providers in Maryland.

See all radiation oncology providers in Maryland

Medicare billing

Part B allowed, 2024
$238,430
Medicare patients
82
Services billed
1,093

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone Hcl27$302
Gabapentin15$149

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →